~500 million people worldwide who are affected by osteoarthritis
There are an estimated 500 million people worldwide who are affected by osteoarthritis, a disease which can cause excruciating pain and make everyday tasks difficult or impossible.
AAV vector to induce expression of clinically validated proteins to target osteoarthritis
Remedium Bio is developing a gene therapy asset which utilizes an FDA-approved AAV vector to induce expression of clinically validated proteins to target mild-moderate osteoarthritis.
USD 20B market
Remedium Bio is aiming to capture the USD 20B mild-moderate osteoarthritis market, which currently has no FDA-approved therapies.
“[The company has a] efficient approach to product development – modular application of proven technologies for the treatment of well characterized pathologies, with a focus on its lead candidate gene therapy, the only single-injection treatment potentially capable of increasing cartilage thickness in Osteoarthritic joints."
Frank Luppino (CEO of Remedium Bio)